Cinacalcet
- Generic Name
- Cinacalcet
- Brand Names
- Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22F3N
- CAS Number
- 226256-56-0
- Unique Ingredient Identifier
- UAZ6V7728S
- Background
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
- Indication
For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
- Associated Conditions
- Hypercalcemia, Secondary Hyperparathyroidism (SHPT)
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
Phase 3
Completed
- Conditions
- Secondary HyperparathyroidismEnd Stage Renal Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT00037635
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath